Skip to main content
Top
Published in: Cancer Causes & Control 8/2018

01-08-2018 | Brief report

Gestational diabetes, type II diabetes, and mammographic breast density in a U.S. racially diverse population screened for breast cancer

Authors: Sabine Oskar, Natalie J. Engmann, Aisia R. Azus, Parisa Tehranifar

Published in: Cancer Causes & Control | Issue 8/2018

Login to get access

Abstract

Purpose

Type II diabetes mellitus (T2DM) has consistently been associated with an increased risk of breast cancer, but the association of gestational diabetes mellitus (GDM) with breast cancer is less clear. T2DM and GDM may influence breast cancer risk through mammographic breast density, a strong risk factor for breast cancer. We examined whether T2DM and GDM are associated with higher mammographic breast density in a largely racial/ethnic minority sample.

Methods

We collected digital mammograms, anthropometric measures, and interview data from 511 racially diverse women recruited during screening mammography appointments between 2012 and 2016 (mean age 51 years; 70% Hispanic). We examined the associations of self-reported GDM, T2DM, and medication use (metformin and insulin) with mammographic breast density, measured as percent and area of dense tissue using Cumulus software.

Results

In multivariable linear regression models, history of T2DM and/or GDM and length of time since diagnosis were not associated with percent density or dense breast area, either before or after adjustment for current BMI. Use of metformin in diabetic women was associated with lower percent density (β = − 5.73, 95% CI − 10.27, − 1.19), only before adjusting for BMI. These associations were not modified by menopausal status.

Conclusions

Our results do not support associations between T2DM and/or GDM and higher amount of mammographically dense breast tissue, suggesting that the mechanism linking diabetes with breast cancer risk may not include mammographic breast density in midlife.
Literature
1.
go back to reference Centers for Disease Control and Prevention (2017) National Diabetes Statistics Report, 2017. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta Centers for Disease Control and Prevention (2017) National Diabetes Statistics Report, 2017. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta
2.
go back to reference DeSisto CL, Kim SY, Sharma AJ (2014) Prevalence estimates of gestational diabetes mellitus in the United States, pregnancy risk assessment monitoring system (prams), 2007–2010. Prev Chronic Dis 11:130415CrossRef DeSisto CL, Kim SY, Sharma AJ (2014) Prevalence estimates of gestational diabetes mellitus in the United States, pregnancy risk assessment monitoring system (prams), 2007–2010. Prev Chronic Dis 11:130415CrossRef
4.
go back to reference Tong G-X, Cheng J, Chai J et al (2014) Association between gestational diabetes mellitus and subsequent risk of cancer: a systematic review of epidemiological studies. Asian Pac J Cancer Prev 15(10):4265–4269CrossRefPubMed Tong G-X, Cheng J, Chai J et al (2014) Association between gestational diabetes mellitus and subsequent risk of cancer: a systematic review of epidemiological studies. Asian Pac J Cancer Prev 15(10):4265–4269CrossRefPubMed
5.
go back to reference Powe CE, Tobias DK, Michels KB et al (2017) History of gestational diabetes mellitus and risk of incident invasive breast cancer among parous women in the Nurses’ Health Study II prospective cohort. Cancer Epidemiol Biomarkers Prev 26(3):321–327CrossRefPubMed Powe CE, Tobias DK, Michels KB et al (2017) History of gestational diabetes mellitus and risk of incident invasive breast cancer among parous women in the Nurses’ Health Study II prospective cohort. Cancer Epidemiol Biomarkers Prev 26(3):321–327CrossRefPubMed
6.
go back to reference Park Y-MM, O’Brien KM, Zhao S, Weinberg CR, Baird DD, Sandler DP (2017) Gestational diabetes mellitus may be associated with increased risk of breast cancer. Br J Cancer 116(7):960–963CrossRefPubMedPubMedCentral Park Y-MM, O’Brien KM, Zhao S, Weinberg CR, Baird DD, Sandler DP (2017) Gestational diabetes mellitus may be associated with increased risk of breast cancer. Br J Cancer 116(7):960–963CrossRefPubMedPubMedCentral
7.
go back to reference Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227–236CrossRefPubMed Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227–236CrossRefPubMed
8.
go back to reference van Duijnhoven FJB, Peeters PHM, Warren RML et al (2007) Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol 25(11):1323–1328CrossRefPubMed van Duijnhoven FJB, Peeters PHM, Warren RML et al (2007) Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol 25(11):1323–1328CrossRefPubMed
9.
go back to reference Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P (2013) Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 31(18):2249–2256CrossRefPubMedPubMedCentral Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P (2013) Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 31(18):2249–2256CrossRefPubMedPubMedCentral
10.
go back to reference Cuzick J, Warwick J, Pinney E et al (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. JNCI J Natl Cancer Inst 103(9):744–752CrossRefPubMed Cuzick J, Warwick J, Pinney E et al (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. JNCI J Natl Cancer Inst 103(9):744–752CrossRefPubMed
11.
go back to reference Byrne C, Ursin G, Martin CF et al (2017) Mammographic density change with estrogen and progestin therapy and breast cancer risk. JNCI J Natl Cancer Inst 109(9):djx001CrossRef Byrne C, Ursin G, Martin CF et al (2017) Mammographic density change with estrogen and progestin therapy and breast cancer risk. JNCI J Natl Cancer Inst 109(9):djx001CrossRef
12.
go back to reference Buschard K, Thomassen K, Lynge E et al (2017) Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort. Cancer Causes Control 28(1):13–21CrossRefPubMed Buschard K, Thomassen K, Lynge E et al (2017) Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort. Cancer Causes Control 28(1):13–21CrossRefPubMed
13.
go back to reference Roubidoux MA, Kaur JS, Griffith KA et al (2003) Correlates of mammogram density in Southwestern Native-American women. Cancer Epidemiol Biomarkers Prev 12(6):552–558PubMed Roubidoux MA, Kaur JS, Griffith KA et al (2003) Correlates of mammogram density in Southwestern Native-American women. Cancer Epidemiol Biomarkers Prev 12(6):552–558PubMed
14.
go back to reference Sellers TA, Jensen LE, Vierkant RA et al (2007) Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study. Cancer Causes Control 18(5):505–515CrossRefPubMed Sellers TA, Jensen LE, Vierkant RA et al (2007) Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study. Cancer Causes Control 18(5):505–515CrossRefPubMed
15.
go back to reference Sanderson M, O’Hara H, Foderingham N et al (2015) Type 2 diabetes and mammographic breast density among underserved women. Cancer Causes Control 26(2):303–309CrossRefPubMed Sanderson M, O’Hara H, Foderingham N et al (2015) Type 2 diabetes and mammographic breast density among underserved women. Cancer Causes Control 26(2):303–309CrossRefPubMed
16.
17.
go back to reference Tehranifar P, Protacio A, Schmitt KM et al (2015) The metabolic syndrome and mammographic breast density in a racially diverse and predominantly immigrant sample of women. Cancer Causes Control 26(10):1393–1403CrossRefPubMedPubMedCentral Tehranifar P, Protacio A, Schmitt KM et al (2015) The metabolic syndrome and mammographic breast density in a racially diverse and predominantly immigrant sample of women. Cancer Causes Control 26(10):1393–1403CrossRefPubMedPubMedCentral
18.
go back to reference Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Draznin B (2001) Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem 276(41):38023–38028PubMed Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Draznin B (2001) Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem 276(41):38023–38028PubMed
19.
go back to reference Gunter MJ, Hoover DR, Yu H et al (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. JNCI J Natl Cancer Inst 101(1):48–60CrossRefPubMed Gunter MJ, Hoover DR, Yu H et al (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. JNCI J Natl Cancer Inst 101(1):48–60CrossRefPubMed
20.
go back to reference Campagnoli C, Berrino F, Venturelli E et al (2013) Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer 13(6):433–438CrossRefPubMed Campagnoli C, Berrino F, Venturelli E et al (2013) Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer 13(6):433–438CrossRefPubMed
21.
Metadata
Title
Gestational diabetes, type II diabetes, and mammographic breast density in a U.S. racially diverse population screened for breast cancer
Authors
Sabine Oskar
Natalie J. Engmann
Aisia R. Azus
Parisa Tehranifar
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 8/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-018-1048-6

Other articles of this Issue 8/2018

Cancer Causes & Control 8/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine